Ignite Creation Date:
2025-12-25 @ 3:48 AM
Ignite Modification Date:
2026-03-17 @ 9:57 PM
Study NCT ID:
NCT02964702
Status:
COMPLETED
Last Update Posted:
2019-07-18
First Post:
2016-11-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Thrombectomy Revascularization of Intracranial Vessel OcclusioN by Originating From Japan (TRON1-Japan)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000083242', 'term': 'Ischemic Stroke'}], 'ancestors': [{'id': 'D020521', 'term': 'Stroke'}, {'id': 'D002561', 'term': 'Cerebrovascular Disorders'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 50}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2016-11-09', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-07', 'completionDateStruct': {'date': '2017-10-23', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-07-17', 'studyFirstSubmitDate': '2016-11-09', 'studyFirstSubmitQcDate': '2016-11-11', 'lastUpdatePostDateStruct': {'date': '2019-07-18', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2016-11-16', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2017-07-25', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'The primary efficacy endpoint of the study is rate of immediate post-procedure reperfusion with the device in 2 pathways/device or 3 pathways/vessel measured using Thrombolysis in Cerebrovascular Infarction (TICI) score of 2a or greater.', 'timeFrame': 'immediate post procedure'}, {'measure': 'The primary safety endpoint of the study is mortality within 90 days after the procedure', 'timeFrame': '90 days'}], 'secondaryOutcomes': [{'measure': 'Proportion of subjects with newly diagnosed embolism accompanied by immediate post-procedure embolectomy', 'timeFrame': 'immediate post-procedure'}, {'measure': 'Rate of reperfusion not accompanied by symptomatic intracranial hemorrhage within 24 hours after the procedure', 'timeFrame': '24 hours'}, {'measure': 'Proportion of subjects who have modified Rankin Scale (mRS) score of 2 or greater whose National Institute of Health Stroke Scale (NIHSS) score improved by 10 points or more from baseline at 90 days post-procedure', 'timeFrame': '90 days'}, {'measure': 'Assessment of mRS scores at 90 days post-procedure', 'timeFrame': '90 days'}, {'measure': 'Assessment of NIHSS scores at 90 days post-procedure', 'timeFrame': '90 days'}, {'measure': 'Assessment of Barthel Index (BI) scores at 90 days post-procedure', 'timeFrame': '90 days'}, {'measure': 'Incidence of intracranial hemorrhage including both symptomatic and asymptomatic within 24 hours after the procedure', 'timeFrame': '24 hours'}, {'measure': 'Incidence of symptomatic intracranial hemorrhage within 24 hours after the procedure', 'timeFrame': '24 hours'}, {'measure': 'Incidence of asymptomatic intracranial hemorrhage within 24 hours after the procedure', 'timeFrame': '24 hours'}, {'measure': 'Incidence of device- or procedure-related serious adverse events within 90 days after the procedure', 'timeFrame': '90 days'}, {'measure': 'Number of any defect in the investigational device', 'timeFrame': 'at the time of inspection before procedure, intraoperative and immediate post-procedure'}]}, 'conditionsModule': {'conditions': ['Acute Ischemic Stroke']}, 'descriptionModule': {'briefSummary': 'To evaluate the efficacy and safety of catheter-based thrombectomy for reperfusion by removing a thrombus in a cerebral blood vessel in patients with acute cerebral infarction (within 8 hours after onset), in whom intravenous administration of tissue plasminogen activator (t-PA) is not indicated or reperfusion cannot be achieved by intravenous t-PA administration.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '85 Years', 'minimumAge': '20 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n1. Patients with neurological disorders caused by blood vessel occlusion associated with acute cerebral infarction\n2. Patients who can receive treatment within 8 hours after onset of symptoms of acute cerebral infarction\n3. Patients in whom intravenous administration of t-PA is not indicated or reperfusion cannot be achieved by intravenous t-PA administration\n4. Patients who have accessible occlusion of the middle cerebral artery (M1 or M2 to 3), basilar artery, vertebral artery, posterior cerebral artery (P1 or P2), anterior cerebral artery (A1 to 2), or intracranial internal carotid artery (pre-procedure TICI score, 0 or 1) as determined by angiography\n5. Patients with an NIHSS score of 8 to 30\n6. Patients with an mRS score of 0 to 2 before onset\n7. Patients aged between 20 and 85 years (at the time of informed consent)\n8. Patients who are able to provide written consent (signature) or whose legally acceptable representative (a person with parental authority, spouse, guardian, and an individual legally responsible for his/her custody) can provide written consent (signature)\n\nExclusion Criteria:\n\n1. Patients who manifest the following:\n\n * Carotid artery dissection\n * Vasculitis\n * An angulated vessel, making it difficult to guide an investigational device\n * Significant (\\>50%) stenosis, making it difficult to guide an investigational device\n * Acute intracranial hemorrhage\n * Mass lesion or intracranial tumor\n * Widespread early ischemic changes revealed by CT or MRI\n2. Patients who have two or more different major cerebrovascular occlusions requiring treatment\n3. Patients with an allergy to contrast agents or who cannot receive them or those who have a serious metal allergy\n4. Patients who received heparin within 48 hours and have Partial Thromboplastin Time (PTT)/Activated Partial Thromboplastin Time (APTT) \\> twice the upper limit of normal\n5. Patients with known bleeding tendencies or coagulation deficiency or who have received oral anticoagulants (such as warfarin), and who have (PT-) International Normalized Ratio (INR) \\>3\n6. Patients with platelet count \\<30,000 /mm3\n7. Patients with blood glucose levels \\<50 mg/dL\n8. Patients with uncontrolled hypertension (systolic BP \\>185 mmHg and diastolic BP \\>110 mmHg)\n9. Patients with expected life expectancy \\<90 days\n10. Female patients who are pregnant or breast feeding\n11. Patients who are participating in clinical trials of drugs or medical devices\n12. Patients disqualified from participation in the study by the investigator (sub-investigator) due to reasons other than the above'}, 'identificationModule': {'nctId': 'NCT02964702', 'acronym': 'TRON1-Japan', 'briefTitle': 'Thrombectomy Revascularization of Intracranial Vessel OcclusioN by Originating From Japan (TRON1-Japan)', 'organization': {'class': 'INDUSTRY', 'fullName': 'JIMRO Co., Ltd.'}, 'officialTitle': 'A Multicenter, Single-arm Study of the Efficacy and Safety of a Thrombectomy Device (T-01) for the Treatment of Acute Cerebral Infarction', 'orgStudyIdInfo': {'id': 'BJSTO-16-01'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Thrombectomy Device(T-01)', 'description': 'Mechanical Thrombectomy with T-01', 'interventionNames': ['Device: Thrombectomy Device T-01']}], 'interventions': [{'name': 'Thrombectomy Device T-01', 'type': 'DEVICE', 'armGroupLabels': ['Thrombectomy Device(T-01)']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Kurume', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'Kurume University Hospital', 'geoPoint': {'lat': 33.31667, 'lon': 130.51667}}, {'city': 'Fukuyama', 'state': 'Hiroshima', 'country': 'Japan', 'facility': 'Brain Attack Center Ota Memorial Hospital', 'geoPoint': {'lat': 34.48333, 'lon': 133.36667}}, {'city': 'Kobe', 'state': 'Hyōgo', 'country': 'Japan', 'facility': 'Kobe City Medical Center General Hospital', 'geoPoint': {'lat': 34.6913, 'lon': 135.183}}, {'city': 'Nishinomiya', 'state': 'Hyōgo', 'country': 'Japan', 'facility': 'Hyogo College of Medicine', 'geoPoint': {'lat': 34.71562, 'lon': 135.33199}}, {'city': 'Tsukuba', 'state': 'Ibaraki', 'country': 'Japan', 'facility': 'University of Tsukuba Hospital', 'geoPoint': {'lat': 36.08333, 'lon': 140.11667}}, {'city': 'Ise', 'state': 'Mie-ken', 'country': 'Japan', 'facility': 'Ise Red Cross Hospital', 'geoPoint': {'lat': 34.48333, 'lon': 136.7}}, {'city': 'Sendai', 'state': 'Miyagi', 'country': 'Japan', 'facility': 'Kohnan Hospital', 'geoPoint': {'lat': 38.26667, 'lon': 140.86667}}, {'city': 'Suita', 'state': 'Osaka', 'country': 'Japan', 'facility': 'National Cerebral and Cardiovascular Center', 'geoPoint': {'lat': 34.76143, 'lon': 135.51567}}, {'city': 'Gifu', 'country': 'Japan', 'facility': 'Gifu University Hospital', 'geoPoint': {'lat': 35.42291, 'lon': 136.76039}}, {'city': 'Kyoto', 'country': 'Japan', 'facility': 'Japanese Red Cross Kyoto Daiichi Hospital', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'city': 'Nagasaki', 'country': 'Japan', 'facility': 'Nagasaki University Hospital', 'geoPoint': {'lat': 32.75, 'lon': 129.88333}}, {'city': 'Wakayama', 'country': 'Japan', 'facility': 'Wakayama Medical University Hospital', 'geoPoint': {'lat': 34.23333, 'lon': 135.16667}}, {'city': 'Yamagata', 'country': 'Japan', 'facility': 'Yamagata City Hospital SAISEIKAN', 'geoPoint': {'lat': 38.23333, 'lon': 140.36667}}], 'overallOfficials': [{'name': 'Nobuyuki Sakai, M.D., D.M. Sc', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Kobe City Medical Center General Hospital'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'JIMRO Co., Ltd.', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}